SeraNovo is proud to announce that in December 2021, Carna Biosciences initiated a clinical study with a drug product based on a joint development program with SeraNovo's eutectic formulation technology.
Niall Hodgins, CEO SeraNovo comments: “This clinical trial marks a huge milestone in our mission to eliminate solubility-related issues of drug candidates. After years of hard work, we have moved our technology from the lab to the clinic. We are confident that the current clinical study will validate our promising preclinical results in humans. In addition, the timely supply of drug product in support of the clinical trial also demonstrates the scalability, manufacturability and regulatory acceptance of our technology.”
About SeraNovo: SeraNovo is an innovative formulation company improving the oral bioavailability of active pharmaceutical ingredients. The focus of the company is on solving the problem of solubility-limited bioavailability by designing tailor-made, eutectic solvent based formulations. SeraNovo is a privately owned company located in Leiden, the Netherlands and as technology inventor owns all know-how and IP. For more information, please visit www.seranovo.com.
About Carna Biosciences: Carna Biosciences is a biopharmaceutical company focused on the discovery and development of kinase inhibitor drugs to treat serious unmet medical needs in oncology, autoimmune and neurological diseases by inhibiting kinases that are important drivers for those diseases. Carna Biosciences was founded in Kobe, Japan, in 2003 as a spinoff of Japan Organon (Nippon Organon KK). Carna’s initial focus was to develop an extensive number of state-of-the-art, highest quality reagents for kinase drug discovery, and has since established a leading drug discovery program with a significant collection of proprietary chemical libraries. For more information, please visit www.carnabio.com.
Forward-Looking Statements: This press release contains forward-looking statements, including but not limited to statements regarding development plans, the DES Formulation Platform, and product candidates and related capabilities. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from current expectations and projections. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required by law.
For further information, please contact us at firstname.lastname@example.org